Initially, the antiproliferative activities of ten new compounds named 2a–e and 3a–e against HCT-116 colorectal carcinoma (both p53-wildtype and p53-knockout cells) and MCF-7 breast carcinoma cells were evaluated using the MTT assay (Table 1). Here, TP53 is linked to breast carcinoma.